High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00953-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Kentarou Takei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacterial Proteins, beta-Lactamases, Enterobacter cloacae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Carbapenemase-producing Enterobacter cloacae complex (CPEC) represents an emerging threat in healthcare settings; however, its spread across local and regional hospitals remains elusive. Between 2014 and 2022, 211 non-duplicate E. cloacae complex isolates (ECC) with reduced carbapenem susceptibility based on automated susceptibility testing were collected from 58 hospitals in 14 prefectures across Japan. PCR detected the bla IMP-1 group in 92.9% of isolates. Among these, 80 representative CPEC isolates underwent whole-genome sequencing. Two dominant high-risk clonal groups, ST78 and ST133 (including single-locus variants), accounted for 62.5% of sequenced isolates. Notably, ST133—rarely reported in Japan—was the second most common type and detected widely, suggesting gradual and inconspicuous dissemination. ST78 exhibited substantial genomic diversity, frequent co-carriage of extended-spectrum beta-lactamase genes, and multiple plasmid replicons, while ST133 formed a more uniform lineage with limited resistance determinants. Most isolates remained highly susceptible to amikacin and cefiderocol. Core-genome multi-locus sequence typing suggested possible intra-facility persistence and inter-facility transmission of closely related strains (≤10 allele differences) in some hospitals over time. Among the 46 facilities with bla IMP-1 group-positive isolates, 73.9% (34/46) were small hospitals (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Infectious Diseases and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
- Department of Bacteriology, BML Inc., Kawagoe, Japan.
ORCID-Profile: Kentarou Takei, Hajime Kanamori, Hiroaki Baba, Tetsuji Aoyagi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Takei, K., Kanamori, H., Sakata, R., Ogawa, M., Baba, H., Takei, Y., Nakayama, A., & Aoyagi, T. (2025). High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00953-25
Vancouver
Takei K, Kanamori H, Sakata R, Ogawa M, Baba H, Takei Y, et al. High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00953-25
BibTeX
@article{Takei2025,
author = {Takei, Kentarou and Kanamori, Hajime and Sakata, Ryuji and Ogawa, Miho and Baba, Hiroaki and Takei, Yumiko and Nakayama, Asami and Aoyagi, Tetsuji},
title = {High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00953-25}
}
EUVIMED